Loading cancer entity…
Subtype
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
Clinical trials
1,589 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (247)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05333523 | Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.(PRIMO) | recruiting | Phase 3 | 242 | Radboud University Medical CenterOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06699212 | A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases(ECLIPSE) | recruiting | Phase 3 | 412 | Rakuten Medical, Inc. |
| 3 |
| Oct 15, 2025 |
| clinicaltrials |
| NCT04459715 | A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) | terminated | Phase 3 | 730 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 26 | Oct 8, 2025 | clinicaltrials |
| NCT04458909 | Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer | terminated | Phase 3 | 15 | National Cancer Institute (NCI)NIH | 4 | Oct 3, 2025 | clinicaltrials |
| NCT03340896 | Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT(SALTORL) | active not recruiting | Phase 3 | 256 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06082167 | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(STELLAR-305) | active not recruiting | Phase 2 / Phase 3 | 600 | ExelixisINDUSTRY | 26 | Aug 17, 2025 | clinicaltrials |
| NCT06492460 | 2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma | recruiting | Phase 3 | 422 | Sun Yat-sen UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT05930938 | Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer(XXL_2022-01) | terminated | Phase 3 | 19 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT02998385 | Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy)(SANTAL) | active not recruiting | Phase 3 | 342 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT02999087 | Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)(REACH) | active not recruiting | Phase 3 | 707 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT03576417 | A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck(NIVOPOSTOP) | active not recruiting | Phase 3 | 680 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT06719479 | A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.). | not yet recruiting | Phase 2 / Phase 3 | 60 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 0 | Dec 5, 2024 | clinicaltrials |
| NCT06601335 | A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | recruiting | Phase 3 | 510 | AkesoINDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06647563 | Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT) | not yet recruiting | Phase 3 | 355 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 0 | Oct 18, 2024 | clinicaltrials |
| NCT03452137 | A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck(IMvoke010) | terminated | Phase 3 | 406 | Hoffmann-La RocheINDUSTRY | 23 | Oct 9, 2024 | clinicaltrials |
| NCT06248996 | a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer Patients(ARTSCAN VI) | recruiting | Phase 3 | 308 | Lund University HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02923258 | Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer | completed | Phase 2 / Phase 3 | 224 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT05582265 | Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I) | recruiting | Phase 3 | 537 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT05798793 | Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma(NEOPCOSCC) | recruiting | Phase 3 | 309 | Hospital of Stomatology, Wuhan UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05125055 | Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC | recruiting | Phase 2 / Phase 3 | 80 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06102395 | Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC | recruiting | Phase 3 | 272 | Beijing Tongren HospitalOTHER | 1 | Oct 30, 2023 | clinicaltrials |
| NCT01864850 | Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC(ELAN-RT) | completed | Phase 3 | 202 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 2 | Sep 22, 2023 | clinicaltrials |
| NCT06016400 | Using Vitamin D to Reduce Oral Mucosal Inflammation in Chemotherapy Patients With Oral Squamous Cell Carcinoma | unknown | Phase 2 / Phase 3 | 412 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT05980715 | PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy(HNC-SYSU-003) | recruiting | Phase 3 | 324 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05802290 | NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN(NIVACTOR) | completed | Phase 3 | 124 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT01855451 | Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma(HPVOropharynx) | unknown | Phase 3 | 189 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Nov 18, 2022 | clinicaltrials |
| NCT00274937 | Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer | completed | Phase 3 | 111 | Children's Oncology GroupNETWORK | 3 | Oct 25, 2022 | clinicaltrials |
| NCT02105636 | Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) | completed | Phase 3 | 361 | Bristol-Myers SquibbINDUSTRY | 15 | Oct 5, 2022 | clinicaltrials |
| NCT01265849 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity(IT-MATTERS) | completed | Phase 3 | 928 | CEL-SCI CorporationINDUSTRY | 23 | Aug 19, 2022 | clinicaltrials |
| NCT05044117 | Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) | recruiting | Phase 3 | 220 | Sun Yat-sen UniversityOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT04129320 | Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 2 / Phase 3 | 0 | MacroGenicsINDUSTRY | 0 | Feb 8, 2022 | clinicaltrials |
| NCT01950689 | NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)(NIMRAD) | completed | Phase 3 | 338 | The Christie NHS Foundation TrustOTHER | 1 | Oct 19, 2021 | clinicaltrials |
| NCT02551159 | Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer(KESTREL) | completed | Phase 3 | 823 | AstraZenecaINDUSTRY | 23 | Oct 13, 2021 | clinicaltrials |
| NCT03349710 | Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer | completed | Phase 3 | 74 | Bristol-Myers SquibbINDUSTRY | 10 | Aug 9, 2021 | clinicaltrials |
| NCT01427478 | Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck(BIBW2992ORL) | completed | Phase 3 | 134 | Centre Leon BerardOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT03673735 | Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC(ADHERE) | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | May 10, 2021 | clinicaltrials |
| NCT02661152 | DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.(DAHANCA30) | unknown | Phase 3 | 1,252 | Danish Head and Neck Cancer GroupNETWORK | 1 | Apr 13, 2021 | clinicaltrials |
| NCT04780750 | Concurent Chemoradiotherapy in Head and Neck Cancers | unknown | Phase 3 | 60 | Assiut UniversityOTHER | 0 | Mar 3, 2021 | clinicaltrials |
| NCT03908372 | Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 120 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT02236936 | Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck(AGMT_HNO_PN) | terminated | Phase 3 | 8 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | May 1, 2020 | clinicaltrials |
| NCT00609284 | Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux(2007-01) | completed | Phase 3 | 406 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Apr 15, 2020 | clinicaltrials |
| NCT04146402 | SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma | unknown | Phase 3 | 330 | Sinocelltech Ltd.INDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT04137627 | Melatonin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma | completed | Phase 3 | 50 | Indonesia UniversityOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT03855384 | Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN） | unknown | Phase 3 | 334 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT02715596 | Changes in Body Composition After EPA Supplementation in Head and Neck Patients(hepaneck) | completed | Phase 3 | 54 | Institut Català d'OncologiaOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT00442455 | Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck | completed | Phase 3 | 53 | Grupo de Investigación Clínica en Oncología RadioterapiaOTHER | 1 | Jun 6, 2019 | clinicaltrials |
| NCT02347332 | Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer | completed | Phase 3 | 459 | Pierre Fabre MedicamentINDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01233843 | Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux.(2007/02) | completed | Phase 3 | 370 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT00999700 | Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin(INTERCEPTOR) | unknown | Phase 3 | 282 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 5, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Nov 24, 2025source: clinicaltrials